The manufacturer presented differences in HbA1c change at 52 weeks from its meta-analysis (complete with 95% credible intervals [95% CrI]) for canagliflozin 100 mg and 300 mg compared with the different comparators as dual therapy with a metformin background. Canagliflozin 100 mg produced a numerically greater reduction in HbA1c than sitagliptin 100 mg (-0.01%, 95% CrI -0.48 to 0.44) and dapagliflozin 10 mg (-0.14%, 95% CrI -0.81 to 0.47), but not liraglutide 1.2 mg (0.40%, 95% CrI -0.33 to 1.11), canagliflozin 300 mg (0.13%, 95% CrI -0.25 to 0.52), pioglitazone 30 mg (0.11%, 95% CrI -0.44 to 0.84), exenatide 10 micrograms (0.02%, 95% CrI -0.65 to 0.55) or glimepiride (0.00%, 95% CrI -0.45 to 0.46). Canagliflozin 300 mg was associated with a numerically greater reduction in HbA1c than pioglitazone 30 mg (-0.02%, 95% CrI -0.57 to 0.72), exenatide 10 micrograms (-0.11%, 95% CrI -0.78 to 0.42), glimepiride (-0.13%, 95% CrI -0.58 to 0.33), canagliflozin 100 mg (-0.13%, 95% CrI -0.52 to 0.25), sitagliptin 100 mg (-0.14%, 95% CrI -0.61 to 0.31) and dapagliflozin 10 mg (-0.27%, 95% CrI -0.94 to 0.34). However, it was not associated with a numerically greater reduction in HbA1c compared with liraglutide 1.2 mg (0.27%, 95% CrI -0.46 to 0.98).